Impact of new medications on the treatment of immune TTP
Scully, Marie Howells, Lara Lester, William A
Scully, Marie
Howells, Lara
Lester, William A
Abstract
The last decade has seen the introduction of 2 new licensed therapies for thrombotic thrombocytopenic purpura (TTP), caplacizumab and recombinant ADAMTS13 (rADAMTS13), for immune and congenital TTP (cTTP), respectively. They improve acute TTP outcomes, and reduce the need for plasma therapy, time to clinical response, and treatment burden. Future pathways need to replace plasma exchange in acute TTP and optimize/personalize rADAMTS13 in cTTP. Future emphasis should focus on additional monoclonals/treatments to tackle ADAMTS13 antibodies.
MIDER Authors
Date
2025-02-06
Type
Article
Subject
Thrombosis, Fibrinolytic agents, Haematology, Haematologic diseases
Collections
Citation
Scully M, Howells L, Lester WA. Impact of new medications on the treatment of immune TTP. Blood. 2025 Mar 27;145(13):1353-1357. doi: 10.1182/blood.2024026390.
Journal / Source Title
blood
DOI
10.1182/blood.2024026390
PMID
39912777
Publisher
Elsevier
Publisher’s URL
https://ashpublications.org/blood